Edit |   |
Antigenic Specificity | Cripto-1 TDGF1 |
Clone | polyclonal |
Host Species | Rabbit |
Reactive Species | human |
Isotype | n/a |
Format | immunoaffinity purified |
Size | 25 µL |
Concentration | 0.80 mg/mL |
Applications | ELISA, Immunohistochemistry, Western Blot. This affinity purified antibody has been tested for use in ELISA and western blotting. Specific conditions for reactivity should be optimized by the end user. Expect a band approximately 21 kDa in size corresponding to Cripto-1 by western blotting in the appropriate cell lysate or extract. Cripto-1 is reported as a 188 amino acid protein with a molecular weight of 21.1 kDa. |
Reviews / Ratings | If you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY. |
Description | This product was affinity purified from monospecific antiserum by immunoaffinity chromatography. This antibody is specific for human Cripto-1 protein. A BLAST analysis was used to suggest limited cross-reactivity with Cripto-1 from mouse based on a 70% homology with the immunizing sequence. Expect cross-reactivity with human Cripto-3 (TDGF2) based on very high levels of sequence conservation. Cross-reactivity with Cripto-1 from other sources has not been determined. |
Immunogen | This affinity purified antibody was prepared from whole rabbit serum produced by repeated immunizations with a synthetic peptide corresponding to an internal sequence of human Cripto-1 protein. |
Other Names | rabbit anti-Cripto 1 antibody, rabbit anti-Cripto-1 antibody, Cripto 1 growth factor antibody, Epidermal growth factor like cripto protein CR1 antibody, TDGF 1 antibody, Teratocarcinoma-derived growth factor 1, CRGF, TDGF1 |
Gene, Accession # | TDGF1, Gene ID: 6997, NCBI: 4507425, UniProt: P13385 |
Catalog # | 600-401-997S |
Price | |
Order / More Info | Cripto-1 TDGF1 Antibody from ROCKLAND IMMUNOCHEMICALS INC. |
Product Specific References | Ligtenberg MA, Witt K, Galvez-Cancino F, Sette A, Lundqvist A, Lladser A, Kiessling R. (2016) Cripto-1 vaccination elicits protective immunity against metastatic melanoma. Oncoimmunology. 2016 Jan 8;5(5):e1128613. doi: 10.1080/2162402X.2015.1128613. eCollection 2016 May. |